Table of Content


List of Tables
List of Figures
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Recurrent Malignt Glioma - Overview
Recurrent Malignt Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Recurrent Malignt Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Recurrent Malignt Glioma - Companies Involved in Therapeutics Development
Anew Oncology Inc
Candel Therapeutics
GtreeBNT Co Ltd
Hebei Senlang Biotechnology Inc Ltd
Immunomic Therapeutics Inc
InSight Biopharmaceuticals Ltd
PharmAbcine Inc
Stella Pharmaceuticals Pvt Ltd
Recurrent Malignt Glioma - Drug Profiles
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
borofalan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Low-Grade Glioma and Recurrent Malignt Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIGB-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
disufenton sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target EphA2 for Recurrent Malignt Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target IL-13 for Malignt Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITI-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rQNestin-34.5v.2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SENL-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignt Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recurrent Malignt Glioma - Dormant Projects
Recurrent Malignt Glioma - Discontinued Products
Recurrent Malignt Glioma - Product Development Milestones
Featured News & Press Releases
Apr 21, 2017: Japan’s Ministry of Health, Labour and Welfare Announces SAKIGAKE Desigtion For Stella Pharma’s Cancer Drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Recurrent Malignant Glioma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Recurrent Malignant Glioma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Recurrent Malignant Glioma - Pipeline by Anew Oncology Inc, H1 2020
Recurrent Malignant Glioma - Pipeline by Candel Therapeutics, H1 2020
Recurrent Malignant Glioma - Pipeline by GtreeBNT Co Ltd, H1 2020
Recurrent Malignant Glioma - Pipeline by Hebei Senlang Biotechnology Inc Ltd, H1 2020
Recurrent Malignant Glioma - Pipeline by Immunomic Therapeutics Inc, H1 2020
Recurrent Malignant Glioma - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020
Recurrent Malignant Glioma - Pipeline by PharmAbcine Inc, H1 2020
Recurrent Malignant Glioma - Pipeline by Stella Pharmaceuticals Pvt Ltd, H1 2020
Recurrent Malignant Glioma - Dormant Projects, H1 2020
Recurrent Malignant Glioma - Dormant Projects, H1 2020 (Contd..1), H1 2020
Recurrent Malignant Glioma - Discontinued Products, H1 2020